Balyasny Asset Management
ELTX icon

Balyasny Asset Management’s Elicio Therapeutics ELTX Stock Holding History

Balyasny Asset Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.62M Buy
244,814
+106,052
+76% +$1.02M ﹤0.01% 1669
2025
Q4 		$1.1M Sell
138,762
-9,314
-6% -$84.5K ﹤0.01% 2148
2025
Q3 		$1.62M Buy
+148,076
New +$1.5M ﹤0.01% 1903

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Balyasny Asset Management's ELTX Position: Q1 2026 in Review

Balyasny Asset Management increased its Elicio Therapeutics (ELTX) stake by 76% in Q1 2026, buying an estimated $1.02M and bringing the position to 244,814 shares worth $2.62M. The position accounts for ﹤0.01% of the portfolio, ranked #1669.

Balyasny Asset Management first reported a position in ELTX in Q3 2025 and has held it in 3 quarters since. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

  • Balyasny Asset Management held 244,814 shares of Elicio Therapeutics worth $2.62M as of Q1 2026.
  • Balyasny Asset Management bought 106,052 Elicio Therapeutics shares in Q1 2026, an estimated $1.02M.
  • Elicio Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1669 holding.
  • Balyasny Asset Management first reported a position in Elicio Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.